Results 81 to 90 of about 43,490 (164)

3D spatial sampling to quantify morphologic heterogeneity in isocitrate dehydrogenase-wildtype glioblastoma. [PDF]

J Neuropathol Exp Neurol
Voong V, Beccari S, Hashemi E, Kriener B, Mathur R, Lafontaine M, Shai A, Lupo JM, Chang EF, Hervey-Jumper SL, Berger MS, Waszak SM, Costello JF, Phillips JJ.   +13 more
europepmc   +1 more source

Poor diagnostic value of isocitrate dehydrogenase 1 R132H immunohistochemistry for determination of isocitrate dehydrogenase 1 status in patients with glioblastoma. [PDF]

Surg Neurol Int
Faried A, Hadi EJ, Agustina H.
europepmc   +1 more source

Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology. [PDF]

Asia Pac J Clin Oncol
Pinkham MB, Sim HW, Jeffree RL, Lasocki A, Legge DM, Saran F, Satgunaseelan L, Gan HK.   +7 more
europepmc   +1 more source

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia. [PDF]

Adv Ther
Watts JM, Wang ES, Jonas BA, Wilson FR, Park JE, Cope S, Sheppard A, Thomassen A, de Botton S, Cortes JE.   +9 more
europepmc   +1 more source

Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas. [PDF]

Neuro Oncol
Arakawa Y, Saito R, Kanemura Y, Mishima K, Koriyama S, Narita Y, Kumabe T, Motomura K, Sugiyama K, Yamasaki F, Mukasa A, Kanamori M, Kuga D, Nagane M, Kakurai Y, Isobe K, Nakamura H.   +16 more
europepmc   +1 more source

Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. [PDF]

Neuro Oncol
Schiff D, Ye X, Li J, Ellingson BM, Wen PY, Walbert T, Campian J, Nabors LB, Ozer BH, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra RS.   +14 more
europepmc   +1 more source

Isocitrate dehydrogenase (IDH)

, 2015
Frank Gaillard, Arlene Campos, Joshua Yap   +2 more
openaire   +1 more source

Histopathological grading affects survival in patients with isocitrate dehydrogenase-wildtype gliomas. [PDF]

Front Oncol
Hou Z, Liu D, Hou Z, Zhang H, Wang H.
europepmc   +1 more source

Some properties of yeast isocitrate dehydrogenase [PDF]

Biochemical Journal, 1972
openaire   +2 more sources

Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis. [PDF]

Cancer Cell
Dang D, Deogharkar A, McKolay J, Smith KS, Panwalkar P, Hoffman S, Tian W, Ji S, Azambuja AP, Natarajan SK, Lum J, Bayliss J, Manzeck K, Sweha SR, Hamanishi E, Pun M, Patel D, Rau S, Animasahun O, Achreja A, Ogrodzinski MP, Diessl J, Cotter J, Hawes D, Yang F, Doherty R, Franson AT, Hanaford AR, Eberhart CG, Raabe EH, Orr BA, Wechsler-Reya RJ, Chen B, Lyssiotis CA, Shah YM, Lunt SY, Banerjee R, Judkins AR, Prensner JR, Koschmann C, Waszak SM, Nagrath D, Simoes-Costa M, Northcott PA, Venneti S.   +44 more
europepmc   +1 more source